MicroRNA and metabolomics signatures for adrenomyeloneuropathy disease severity

Adrenomyeloneuropathy (AMN), the slow progressive phenotype of adrenoleukodystrophy (ALD), has no clinical plasma biomarker for disease progression. This feasibility study aimed to determine whether metabolomics and micro‐RNA in blood plasma provide a potential source of biomarkers for AMN disease s...

Descripción completa

Detalles Bibliográficos
Autores principales: Turk, Bela Rui, Poisson, Laila Marie, Nemeth, Christina Linnea, Goodman, Jordan, Moser, Ann B., Jones, Richard Owen, Fatemi, Ali, Singh, Jaspreet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626672/
https://www.ncbi.nlm.nih.gov/pubmed/36341174
http://dx.doi.org/10.1002/jmd2.12323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626672/
https://www.ncbi.nlm.nih.gov/pubmed/36341174
http://dx.doi.org/10.1002/jmd2.12323

Ejemplares similares